Can follistatin help build muscle?

Research shows that inhibiting myostatin (which follistatin does) promotes muscle growth. However, follistatin is a complex protein that is difficult to administer effectively, and no approved products exist for this purpose.

Is follistatin the same as myostatin inhibitor?

Follistatin is one of the body's natural myostatin inhibitors. There are also other approaches to myostatin inhibition being researched, including antibodies and receptor decoys.

Is follistatin banned in sports?

Yes. Follistatin and other myostatin inhibitors are prohibited by WADA under the category of 'Other Anabolic Agents' (S1.2).

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Hormonal & Endocrine•Updated 2026-02-01•5 min read

What Is Follistatin? Benefits, Research & Safety

A natural glycoprotein that inhibits myostatin and activins, researched for muscle growth and metabolic effects.

Share:X Post LinkedIn

Also known as:

FST

Activin-Binding Protein

DAnimal/cell evidence onlyUK: Unlicensed (UK)WADA: Prohibited in sport

UK summary: Not a licensed UK medicine. Myostatin inhibitor with research interest in muscular dystrophy and other muscle-wasting conditions. Prohibited at all times under WADA S1.2 (other anabolic agents). Some commercial preparations are gene-therapy constructs, not peptides — verify what's actually being sold.

Quick Facts

Overview

Follistatin is a single-chain glycoprotein that functions as an antagonist of several members of the TGF-β superfamily, most notably activins and myostatin. By binding to and neutralising myostatin, follistatin has potent effects on muscle growth and has attracted significant interest in the fitness and research communities. Myostatin is a negative regulator of muscle growth—it limits how large muscles can become. Animals and humans with myostatin mutations show dramatic muscle hypertrophy. Follistatin, by inhibiting myostatin, effectively removes this brake on muscle development. Multiple isoforms of follistatin exist (FS288, FS303, FS315, and FS344), arising from alternative splicing and post-translational modifications. These differ in their tissue distribution, half-lives, and biological activities. Research has explored follistatin for potential applications in muscular dystrophy, sarcopenia (age-related muscle loss), and as an anabolic agent for muscle growth. Gene therapy approaches using follistatin have shown promising results in animal models and early human trials for muscular dystrophy. Follistatin is not approved for human use as a performance-enhancing agent and is prohibited by WADA. Its complexity (being a large glycoprotein rather than a simple peptide) also creates challenges for therapeutic development.

Evidence standards summary

Follistatin — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

Not a licensed UK medicine. Myostatin inhibitor with research interest in muscular dystrophy and other muscle-wasting conditions. Prohibited at all times under WADA S1.2 (other anabolic agents). Some commercial preparations are gene-therapy constructs, not peptides — verify what's actually being sold.

02Human evidence grade

ETheoretical / insufficientStrength of evidence from published human trials.

03Preclinical evidence grade

BModerate human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Not licensed. Research compound only.
EU: Not approved for any indication.
Notes: Follistatin is not approved for muscle enhancement anywhere. Gene therapy approaches are in clinical trials for muscular dystrophies. It is prohibited by WADA. Products sold outside research settings have uncertain quality and authenticity.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Doubles muscle mass by inhibiting myostatin.
Treats muscular dystrophy at home.
Safe injectable peptide for bodybuilders.
Undetectable in drug tests.

07Common internet claims

Marketed in bodybuilding stacks as the ultimate myostatin inhibitor.
Sold by online retailers as research-only peptide (often mis-described — some products are gene-therapy constructs, not the protein).
Promoted via 'follistatin gene therapy' clinics overseas.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Builds muscle without steroids or HGH”	D	Limited	High	Animal-model evidence shows myostatin-inhibition muscle effects; human-outcomes evidence in healthy adults is limited and clinical use is research-only.
“Safe alternative to anabolic agents”	E	No	High	Prohibited under WADA S1.2 as an 'other anabolic agent'; safety profile in healthy adults is not established.
“Available as injection peptide from research suppliers”	E	No	High	Some 'follistatin' products on the grey market are mis-described or are gene-therapy constructs. Identity and purity unverified.
“Treats muscle-wasting conditions”	D	Limited	High	Clinical research is ongoing; no licensed UK follistatin medicine exists.

09Safety uncertainty score

Very high

Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.

10Known adverse signals

Theoretical reproductive disruption (follistatin antagonises activin in HPG axis).
Theoretical tendon weakness with disproportionate muscle growth.
Unknown chronic effects of sustained myostatin suppression.
Gene-therapy versions carry serious vector-related risks (immune response, integration).

11Drug-interaction uncertainty

High

Interaction picture sparse; meaningful uncertainty when combined with other medicines.

12Anti-doping status

WADA: Prohibited in sportWADA strict-liability framing applies.

13UK legal position

UK: Unlicensed (UK)

Not licensed. Research compound only.

Read the full UK legal guide → Peptides and athletes (UK)

14EU legal position

Not approved for any indication.

15What this page cannot tell you

Whether a UK-purchased 'follistatin' product contains the protein or is something else entirely.
Long-term consequences of myostatin pathway suppression in humans.
Whether tendons and connective tissue can match the rate of muscle growth produced.
WADA detection windows — assume detection, strict-liability applies.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Phase 2 / 3 trials in muscular dystrophy underway but no licensed product.
Healthy-adult muscle-building outcome data absent.
Long-term safety entirely unstudied.
Gene-therapy follistatin trials are early-stage with significant safety questions.

19Safer alternatives / established care pathways

Progressive resistance training with adequate protein — the only evidence-based muscle-growth intervention.
Neuromuscular-disease specialist referral for genuine muscle-wasting conditions; licensed treatments exist for some.
Endocrinology / sports medicine review for atypical muscle weakness.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is Follistatin a licensed UK medicine?
Are there UK clinical trials for the muscle condition I'm asking about?
What licensed treatments exist for muscle wasting in my situation?
If I'm an athlete, what is the WADA position?
If a clinic is offering 'follistatin', what is it actually selling — peptide or gene therapy?

Discovery & History

Follistatin was discovered in the late 1980s in ovarian follicular fluid, where it was found to suppress follicle-stimulating hormone (FSH) release from the pituitary—hence the name. Initial research focused on its reproductive endocrine functions. The discovery that follistatin bound to activins explained its FSH-suppressing effects, as activins are key regulators of FSH synthesis. This led to understanding of follistatin's broader role as an activin-binding protein. A pivotal discovery came with the identification that follistatin also binds to and inhibits myostatin. This was particularly exciting given the dramatic muscular hypertrophy seen in myostatin-deficient animals (like the Belgian Blue cattle and "mighty mice"). Research by Se-Jin Lee (who discovered myostatin) and others demonstrated that follistatin could promote muscle growth by inhibiting myostatin. This made follistatin an attractive target for conditions involving muscle wasting. Gene therapy approaches using viral vectors to deliver follistatin genes have been tested in muscular dystrophy patients, with some promising results. Jerry Mendell and colleagues at Nationwide Children's Hospital have conducted notable trials. Follistatin has also gained attention in the bodybuilding community, though the practical challenges of administering a complex glycoprotein and obtaining genuine product are significant.

Mechanism of Action

Follistatin exerts its effects primarily through binding and neutralising TGF-β superfamily members: **Myostatin Inhibition** The primary mechanism of interest for muscle growth: - Binds to myostatin with high affinity - Prevents myostatin from activating its receptor (ActRIIB) - Removes the "brake" on muscle growth - Results in increased muscle mass and strength in studies **Activin Inhibition** Follistatin also neutralises activins: - Activins have various roles in reproduction, development, and inflammation - Activin inhibition may contribute to some metabolic effects - Relevant to reproductive endocrinology applications **Effects on Muscle Growth** The downstream effects of myostatin inhibition: - Increased satellite cell activation - Enhanced muscle protein synthesis - Possible hyperplasia (more muscle fibers) in addition to hypertrophy - Improved muscle repair and regeneration **Metabolic Effects** Research suggests effects beyond muscle: - May improve insulin sensitivity - Potential effects on fat mass (reduction) - Possible brown fat activation - Metabolic benefits may be secondary to increased muscle

Researched Benefits

Based on preclinical and clinical research findings:

1
Significant muscle hypertrophy in animal and gene therapy studies
2
Potential treatment for muscular dystrophies
3
May counteract age-related muscle loss (sarcopenia)
4
Possible improvement in muscle function
5
Research suggests metabolic benefits
6
Effects on fat mass reduction

Claim vs Evidence

How popular claims about Follistatin stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Builds muscle without steroids or HGH”	D	Limited	High	Animal-model evidence shows myostatin-inhibition muscle effects; human-outcomes evidence in healthy adults is limited and clinical use is research-only.
“Safe alternative to anabolic agents”	E	No	High	Prohibited under WADA S1.2 as an 'other anabolic agent'; safety profile in healthy adults is not established.
“Available as injection peptide from research suppliers”	E	No	High	Some 'follistatin' products on the grey market are mis-described or are gene-therapy constructs. Identity and purity unverified.
“Treats muscle-wasting conditions”	D	Limited	High	Clinical research is ongoing; no licensed UK follistatin medicine exists.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Not established for exogenous protein administration
Frequency	N/A
Duration	N/A
Notes	⚠️ Follistatin is not approved for human performance enhancement. Gene therapy approaches are under clinical investigation for muscular dystrophies. Exogenous follistatin protein is challenging to administer effectively. Products sold as follistatin may have quality concerns.

Administration Routes

Routes studied in research settings (educational only):

Gene therapy (clinical trials for muscular dystrophy)
Subcutaneous injection (research, with challenges)

Half-Life	Stability
Variable by isoform; generally short for circulating protein	Complex glycoprotein requiring careful handling

Safety Profile & Known Risks

Commonly Reported Side Effects

Limited human data for protein administration
Gene therapy trials have generally been well tolerated

Rare Risks & Concerns

Unknown long-term effects of sustained myostatin inhibition
Theoretical concerns about tendon/ligament adaptation
Potential effects on heart muscle (also expresses myostatin receptor)
Reproductive effects possible (activin inhibition)

Contraindications

Pregnancy (TGF-β family important for development)
Cardiovascular disease (caution)
Growing individuals (effects on growth plates unclear)

UK & EU Regulatory Context

🇬🇧 United Kingdom

Not licensed. Research compound only.

🇪🇺 European Union

Not approved for any indication.

Follistatin is not approved for muscle enhancement anywhere. Gene therapy approaches are in clinical trials for muscular dystrophies. It is prohibited by WADA. Products sold outside research settings have uncertain quality and authenticity.

Clinical Studies Summary

Frequently Reported Blood Biomarkers in Sarcopenia Clinical Trials: A Systematic Review and Meta-Analysis.

There is an urgent need to adopt recommendations regarding muscle-specific BBMs to be assessed in sarcopenia RCTs. Developing a standardised Core Outcome Set for sarcopenia intervention studies would enhance the standardisation of sarcopenia RCTs and ultimately improve disease management.

Aging Cell. 2026View on PubMed

Circulating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.

Elevated circulating IGF-1 and, to a lesser extent, GDF-15, may be promising biomarkers for sarcopenia. Larger, longitudinal studies are needed to address heterogeneity and causality.

J Gerontol A Biol Sci Med Sci. 2026View on PubMed

Exercise training-induced changes in exerkine concentrations may be relevant to the metabolic control of type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials.

Exercise training represents an anti-inflammatory therapy and metabolism-improving strategy with minimal side effects for patients with type 2 diabetes mellitus.

J Sport Health Sci. 2023View on PubMed

The effects of resistance training on myostatin and follistatin in adults: A systematic review and meta-analysis.

Resistance training in adults is effective for reducing myostatin and increasing follistatin which may contribute to the beneficial effects of resistance training on muscle mass and metabolic outcomes.

Physiol Behav. 2023View on PubMed

Synergistic Effects of Protein Intake and Exercise on Biomarkers of Sarcopenia: A Systematic Review.

Despite heterogeneity in duration and sample size, findings support this combined approach as a promising and clinically applicable strategy to prevent and treat sarcopenia. No external funding was received, and the review is registered in PROSPERO (CRD42025640989).

Biomolecules. 2026View on PubMed

Combined resistance exercise and essential amino acid intake enhance follistatin/myostatin ratio and muscle fitness in older women: a randomized controlled trial.

A 12-week intervention combining resistance exercise and essential amino acid supplementation was superior to either intervention alone in enhancing muscle mass, muscle fitness, myokine profiles, and reducing inflammatory markers among healthy older women.

J Int Soc Sports Nutr. 2026View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 4

Approved product

7 of 7 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

PHASE1/PHASE2

Status: Recruiting · 12 participants · Unlimited Biotechnology LLC

Conditions: Age-related Muscle Decline

No results postedNCT07443826

Stabilization vs Corrective Exercise in PFP

Status: Not Yet Recruiting · 60 participants · Ahram Canadian University

Conditions: Patellofemoral Pain Syndrome

No results postedNCT07465380

HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness

Status: Recruiting · 20 participants · Teachers College, Columbia University

Conditions: Spinal Muscular Atrophy (SMA)

No results postedNCT07488338

Intrauterine Injection of Type III Collage in FST of EC/AEH

PHASE2

Status: Recruiting · 30 participants · Wang Jianliu

Conditions: Atypical Endometrial Hyperplasia, Endometrial Cancer

No results postedNCT07377734

Safety and Efficacy of Klotho and Follistatin Gene Therapy

EARLY_PHASE1

Status: Recruiting · 30 participants · Minicircle

Conditions: Healthy Adults

No results postedNCT07285629

Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma

Status: Not Yet Recruiting · 12 participants · University Hospital, Clermont-Ferrand

Conditions: Cirrhosis With Hepatocellular Carcinoma

No results postedNCT07189624

HABIT-ILE + FST in Children With SMA

Status: Active Not Recruiting · 5 participants · Teachers College, Columbia University

Conditions: SMA - Spinal Muscular Atrophy

No results postedNCT07223320

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Status: Not Yet Recruiting · 10 participants · Peking University People's Hospital

Conditions: Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency

No results postedNCT06549855

Post Exercise Recovery and FST

Status: Not Yet Recruiting · 5 participants · University of British Columbia

Conditions: Exercise Therapy

No results postedNCT06522230

The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis

N/A

Status: Unknown · 60 participants · Assiut University

Conditions: Multiple Sclerosis

No results postedNCT06290453

Evaluation of Serum Follistatin-Like Protein 1 Levels in Behcet's Disease and Its Association With Disease Activity

N/A

Status: Completed · 80 participants · Assiut University

Conditions: Behcet Syndrome

No results postedNCT06730958

Phase I: Safety and Efficacy of an Injectable Follistatin Plasmid Gene Therapy in Humans

PHASE1

Status: Completed · 43 participants · Minicircle

Conditions: Frailty, Aging

No results postedNCT06411366

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Follistatin?

Source research-grade Follistatin from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Follistatin